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Abstract
Background: Neurotrophins (NTs) and their receptors play crucial roles in the development, functions and
maintenance of nervous systems. It is widely believed that NT-induced dimerization of the receptors initiates the
transmembrane signaling. However, it is still controversial whether the receptor molecule has a monomeric or
dimeric structure on the cell surface before its ligand binding.
Findings: Using chemical cross-linking, bimolecular fluorescence complementation (BiFC) and luciferase fragment
complementation (LFC) assays, in this study, we show the brain-derived neurotrophic factor (BDNF) receptor TrkB
exists as a homodimer before ligand binding. We have also found by using BiFC and LFC that the dimer forms in
the endoplasmic reticulum (ER), and that the receptor lacking its intracellular domain cannot form the dimeric
structure.
Conclusions: Most, if not all, of the TrkB receptor has a preformed, yet inactive, homodimeric structure before
BDNF binding. The intracellular domain of TrkB plays a crucial role in the spontaneous dimerization of the newly
synthesized receptors, which occurs in ER. These findings provide new insight into an understanding of a
molecular mechanism underlying transmembrane signaling mediated by NT receptors.
Keywords: BDNF, Chemical crosslinking, Protein fragment complementation assay, Neurotrophin receptor, Pre-
formed homodimer
Findings
The neurotrophin (NT) receptor family consists of the
tropomyosin-related kinase receptors (Trk) A, B and C,
and p75
TNR, a member of the tumor necrosis factor
(TNF) receptor superfamily. TrkA preferentially interacts
with the nerve growth factor (NGF), TrkB with BDNF
and NT-4/5, and TrkC with NT-3. NT-3 can also interact
with TrkA and TrkB with relatively low affinity, and all
the NTs can bind p75
NTR with low affinity [1,2]. The Trk
receptor kinases play crucial roles in the development
and maintenance of the central and peripheral nervous
system, and consist of an extracellular ligand-binding
domain, a single transmembrane domain and an intracel-
lular tyrosine kinase domain. Upon activation, the recep-
tor kinases initiate downstream signaling cascades
mediated by Ras/Raf/MAP kinase, PI3K/Akt and PLC-g
[2-4]. TrkB and its ligand BDNF are highly expressed in
biologically unfavourable neuroblastomas, and TrkB
expression is associated with drug resistance and expres-
sion of angiogenic factors [5].
It is widely believed that the Trk receptor kinases are
activated through NT-induced receptor dimerization.
Because the NT exists in solution as a stable homodi-
mer [6,7], it is thought that the NT dimer acts as a
bridge to induce the dimerization of two Trk mono-
mers. However, we have recently found that TrkA exists
as a preformed, yet inactive, dimer in living cells [8]. In
the present study, therefore, we also examined if TrkB
exists as a preformed dimer in living cells before BDNF
binding.
Preformed TrkB homodimers detected by chemical
crosslinking
We first established a Chinese hamster ovary (CHO) cell
line stably expressing green fluorescent protein (GFP)-
fused TrkB at the receptor’s N-terminus. The GFP-TrkB
fusion protein was inactive in the absence of BDNF, and
could be activated by BDNF added to the culture media,
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phosphorylated TrkB (Figure 1A). The cells were serum-
starved for 2 h at 37°C, followed by an-hour incubation
on ice, in order to increase the cell-surface expression
of the receptor chimera (Figure 1B). Furthermore,
sucrose, 0.45 M at a final concentration, was added to
the culture media in order to inhibit the clathrin-depen-
dent endocytosis of GFP-TrkB upon BDNF binding
[9,10]. Then, the receptor molecules on the cell surface
were chemically cross-linked with BS
3, a membrane-
impermeable cross-linker, in the presence or absence of
BDNF. After the cross-linking, the cell lysates were sub-
jected to Western blotting, and immunostained with
anti-TrkB antibody. In the absence of the cross-linker,
only the lower molecular mass band, ~170 kDa, was
detected, while in the presence of the cross-linker higher
molecular mass band, ~340 kDa, was also recognized by
anti-TrkB antibody in addition to the lower band. Based
on the apparent molecular weights, we assigned the
lower and higher bands as the monomer and dimer of
TrkB, respectively. The band intensity of the TrkB
dimer cross-linked was similar in the absence and pre-
sence of BDNF (Figure 1C). These results suggest either
that a fraction of TrkB exists as a preformed dimer, or
that only a fraction of the receptor dimers was
expressed on the cell surface and was chemically cross-
linked. Furthermore, the results also indicate that the
dimer fraction was not increased after being incubated
with BDNF.
Preformed TrkB homodimers detected by BiFC
To directly observe spontaneous dimerization and subcel-
lular localization of TrkB in living cells, we employed BiFC
[11,12]. The N-terminal and C-terminal fragments of the
Venus fluorescent protein [13], a derivative of yellow
fluorescent protein, were fused to the C-terminus of TrkB,
separately, to make TrkB-VN and TrkB-VC, respectively.
When these constructs were expressed together in the
human embryonic kidney HEK 293 cells, Venus fluores-
cence was clearly observed, whereas no fluorescence was
observed in HEK 293 cells expressing either TrkB-VN or
TrkB-VC, or in cells co-expressing TrkB-VN and the epi-
dermal growth factor receptor (EGFR)-VC as a negative
control (Figure 2A). To exclude again the possibility that
the TrkB dimers were activated due to the BiFC fusion, we
examined the receptor phosphorylation in the absence or
presence of BDNF. In the absence of BDNF, only very low
level of basic autophosphorylation of the fusion receptors
was observed, and BDNF treatment could enhance the
phospholylation of the fused TrkB receptor molecules
(Figure 2B). Together with the results shown in Figure 1A,
these results confirm that the BiFC fusion receptors
behave like the wild-type receptor, and suggest again that
TrkB exists as an inactive dimer, which can be activated
by BDNF binding.
The Venus fluorescence was observed not only on the
cell surface but also inside the cells (Figure 2A, B). To
examine where the Venus reconstitution occurs during
the receptor synthesis, we treated the cells co-expressing
TrkB-VN and TrkB-VC with Brefeldin A (BFA), a lactone
antibiotic that disassembles the Golgi apparatus and
blocks anterograde transport of membrane proteins from
ER to Golgi [14]. In the absence of BFA, Venus fluores-
cence was clearly observed both on the cell surface and
inside the cells (Figure 2C, upper panels), while in the
presence of BFA, Venus fluorescence was observed only
inside the cells (Figure 2C, lower panels). The fluores-
cence inside the cells was mainly co-localized with cal-
nexin, an ER marker [15]. These results indicate that
TrkB spontaneously dimerizes in ER before the newly
synthesized receptor reaches the cell surface. In contrast,
no Venus fluorescence was observed in HEK 293 cells
co-expressing TrkBΔICD-VN and TrkBΔICD-VC, both
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Figure 1 Chemical crosslinking of TrkB on the cell surface. (A)
CHO cells expressing GFP-TrkB were stimulated with (+) or without
(-) 100 ng/ml of BDNF for 5 min at 37°C. The cells were lysed and
subjected to Western blotting with antibodies, a-pTrkB or a-TrkB,
against phosphorylated TrkB or TrkB, respectively. Note that the
fusion receptors were phosphorylated only in the presence of
BDNF. (B) CHO cells expressing GFP-TrkB were serum-starved for 3 h
as described in Methods. Fluorescence signal of GFP were observed
by confocal microscopy. This figure represents > 10 similar images
observed. Bars, 10 μm. (C) CHO cells expressing GFP-TrkB were
serum-starved, and then were incubated with culture media
containing 0.45 M sucrose for 20 min at 37°C. After being incubated
in the presence (+) or absence (-) of 100 ng/ml of BDNF for 5 min
at 37°C, the cells were treated with (+) or without (-) the chemical
cross-linker BS
3 as described in Methods. The cells were lysed and
subjected to Western blotting, with antibody against TrkB. This
figure represents similar results of three independent experiments.
Alpha-tubulin was visualized as a reference. The positions of
molecular weight standards are shown at the right of each panel.
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the presence of BFA (Figure 2D). This confirms that BFA
treatment itself does not induce the Venus reconstitu-
tion, and suggests that the intracellular domain plays a
crucial role in the spontaneous dimerization of TrkB.
Preformed TrkB homodimers detected by LFC
Since the interaction of the BiFC Venus fragments is
irreversible, we cannot determine the ratio of the TrkB
dimer and monomer at equilibrium. Therefore, we
employed firefly LFC because interaction of the lucifer-
ase fragments is reversible [16]. We fused the N-term-
inal or C-terminal fragment of firefly luciferase to the
C-terminus of TrkB, resulting in TrkB-NLuc and TrkB-
CLuc, respectively. When HEK 293 cells co-expressing
T r k B - N L u ca n dT r k B - C L u cw e r ei n c u b a t e dw i t h
luciferin in the absence of BDNF, bioluminescence was
clearly detected although the bioluminescence level was
lower than that of cells expressing pGL3, which encodes
a full-length firefly luciferase (Figure 3A). In contrast,
bioluminescence was not observed in cells co-expressing
TrkBΔICD-NLuc and TrkBΔICD-CLuc, both of which
lacked the intracellular domain of TrkB, in cells co-
expressing TrkBΔICD-NLuc and TrkB-CLuc, or in cells
co-expressing TrkB-NLuc and TrkBΔICD-CLuc. These
results demonstrate that TrkB has a preformed homodi-
meric structure, and its intracellular domain plays a cru-
cial role in the spontaneous dimerization as shown by
the BiFC experiment above (Figure 2D). When the cells
co-expressing TrkB-NLuc and TrkB-CLuc were treated
with 50 or 100 ng/ml BDNF at a final concentration for
10 min at 37°C, the bioluminescence intensity produced
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Figure 2 BiFC assay of TrkB homodimers. (A) HEK 293 cells were transfected with TrkB-VC alone, TrkB-VN alone, TrkB-VN and TrkB-VC, or TrkB-
VN and EGFR-VC. Twenty-four hours after the transfection, Venus fluorescence signals were observed by confocal microscopy. This figure
represents > 20 similar images observed. (B) HEK 293 cells co-expressing TrkB-VN and TrkB-VC were treated with (+) or without (-) 100 ng/ml of
BDNF. The cells were fixed, and immunostained with anti-pTrkB primary antibody and then with fluorescently labeled secondary antibody.
Fluorescence signals of Venus (green) and pTrkB (red) were observed by confocal microscopy. Note that the green and red fluorescence images
do not completely overlap since TrkB-VN and TrkB-VC can form non-fluorescent homodimers. This figure represents > 20 similar images derived
from four independent experiments. Bars, 10 μm. (C, D) HEK 293 cells co-expressing TrkB-VN and TrkB-VC (C), or the fusion receptor pair lacking
the intracellular domain, TrkBΔICD-VN and TrkBΔICD-VC (D) were treated with (+) or without (-) 10 μg/ml BFA. The cells were fixed, and
immunostained with anti-calnexin antibody and then with fluorescently labeled secondary antibody. These figures represent 15 similar images
derived from three independent experiments. Bars, 10 μm.
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untreated with BDNF (Figure 3B). Furthermore, Figure
3C shows that time courses of the bioluminescence
intensity of cells co-expressing TrkB-NLuc and TrkB-
CLuc were very similar each other in the presence or
absence of 100 ng/ml BDNF. These results demonstrate
that most, if not all, of TrkB on the cell surface has a
homodimeric structure before BDNF binding.
In the present study, we have shown that TrkB exists
as a homodimer in living cells before ligand binding, by
using three different approaches, chemical cross-linking,
BiFC and LFC. The results demonstrate that most, if
not all, of the TrkB receptor molecules on the cell sur-
face have homodimeric structures since the addition of
BDNF to the culture media did not induce the dimeriza-
tion at all (Figure 3B, C). The BiFC assay revealed that
the spontaneous dimerization of TrkB occurs in ER
before the newly synthesized receptors reach the cell
surface (Figure 2C). The preformed TrkB homodimer is
inactive since the receptor dimer was phosphorylated
only when incubated with BDNF (Figures 1A and 2B).
Furthermore, it has been demonstrated by both of the
BiFC and LFC assays that the cytoplasmic domain of
TrkB plays an important role in the spontaneous dimer-
ization (Figures 2D and 3A).
An increasing number of studies demonstrate that
many transmembrane receptors, which include receptors
previously thought to be activated by ligand-induced
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Figure 3 LFC assay of TrkB homodimers. (A) HEK 293 cells expressing indicated protein(s) were cultured in a microtiter plate, and then
incubated with luciferin as described in Methods. The red color of the upper panels shows the intensity of bioluminescence produced by the
cells in the microtiter wells, and the lower histogram shows the mean ± S.D. of triplicate experiments. *** p < 0.001. (B) HEK 293 cells expressing
a full-length luciferase or co-expressing TrkB-NLuc and TrkB-CLuc were treated with BDNF at indicated final concentrations for 10 min, and then
incubated with luciferin. The black color of the upper panels shows the intensity of bioluminescence produced by the cells in the micrtotiter
wells. The lower histogram shows the mean intensity ± S.D. of triplicate experiments. (C) HEK 293 cells co-expressing TrkB-NLuc and TrkB-CLuc
were stimulated with 100 ng/ml of BDNF in the presence of luciferin and 0.45 M sucrose to prevent endocytosis as described in Methods. Data
are the mean ± S.D. of triplicate independent experiments.
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homo- and heterodimers in living cells. These receptors
are the aspartate receptor Tar [17], epidermal growth
factor receptor (EGFR) family [12,18-21], erythropoietin
receptor [22], growth hormone receptor (GHR) [23,24],
Toll-like receptor-9 [25], natriuretic peptide receptor A
(NPRA) [26], and nerve growth factor receptor TrkA
[8]. In the cases of EGFR, GHR, NPRA and Tar, it has
been proposed that ligand binding is likely to induce the
rotation/twist of the transmembrane domains of the
preformed receptor dimers, resulting in rearrangement
of the cytoplasmic domains for activation [18,24,26,27].
Therefore, further study of structures of the Trk recep-
tor family will shed light on molecular mechanisms
underlying the receptor activation.
Methods
Plasmid construction
BiFC vectors, pBiFC-VN173 and pBiFC-VC155, were
described previously [28], and FLAG tags encoded by the
vectors were removed as previously described [8]. PCR
products that encode a full-length human TrkB protein
were amplified using pLNCX-hTrkB [29], a generous gift
from Dr. Garrett M. Brodeur (Children’s Hospital of Phi-
ladelphia, PA), as a template and the following primer
pairs: 5’-CCGgaattcACCATGTCGTCCTGGATAAGG
TG (TrkB-VN173-F) and 5’-GCtctagaGCCTAGAATGT
CCAGGTAGAC (TrkB-VN173-R), or 5’-CCGgaattcAC-
CATGTCGTCCTGGATAAGGTG (TrkB-VC155-F) and
5’-CCGctcgagAGCCTAGAATGTCCAGGTAGAC
(TrkB-VC155-R). The PCR products were inserted
between Eco RI and Xba I sites of pBiFC-VN173, or
between Eco RI and Xho I of pBiFC-VC155, resulting in
pTrkB-VN or pTrkB-VC, respectively. Then, a synthetic
double-stranded oligonucleotide, 5’-GGTGGTGGTGGT
TCTGGTGGTGGTGGTTCTGGTGGTGGTGGTTCT
encoding amino-acid residues GGGGSGGGGSGGGGS
termed (G4S)3, were inserted into the unique Xba Io r
Xho I site of pTrkB-VN or pTrkB-VC, respectively. Plas-
mids for firefly (Photinus pyralis) LFC were described
previously [8]. A DNA fragment encoding TrkB was cut
out with Eco RI and Xba I enzymes from pTrkB-VN, and
was then inserted into pBiFC-NLuc and pBiFC-CLuc,
resulting in pTrkB-NLuc and pTrkB-CLuc, respectively.
The construction of pGFP-TrkB was based on pEGFR-
eGFP [30], and a DNA sequence encoding enhanced
GFP, which was amplified by PCR using the primers 5’-C
CGagatctATGGTGAGCAAGGGCGAGGAGCTGTTC
ACC (EGFP-F-BglII) and 5’-CCGgaattcCTTGTACA
GCTCGTCCATGCCGAGAGTGATCC (EGFP-B-EcoRI),
and was then inserted between Bgl II and Eco RI of
pAEMXT-ACPwt-GPI (Covalys Bio-sciences, Witterswil,
Switzerland), resulting in pAEMXT/GFP. A DNA
sequence encoding human TrkB without its signal peptide
(aa 1-31), but with (G4S)3, was inserted between Eco RI
and Xho I of pAEMXT/GFP, resulting in pGFP-TrkB. To
construct various plasmids encoding TrkB lacking its
intracellular domain, a DNA fragment encoding the full-
length TrkB of the expression plasmid constructs was
replaced with a fragment encoding amino-acid residues
1-465 of TrkB. Validity of all the constructs was confirmed
by DNA sequencing and Western blotting.
Cell culture
A HEK 293 cell line was purchased from RIKEN cell bank
(Cat. No.: RCB 1637; Ibaraki, Japan), and was maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Nacalai
Tesque, Kyoto, Japan) supplemented with 10% fetal bovine
serum (FBS; Invitrogen). A CHO-K1 cell line purchased
from the American Type Culture Collection (ATCC; Man-
assas, VA) was maintained in Iscove’sm o d i f i e dD u l b e c c o ’s
medium (IMDM; Invitrogen). All media were supplemen-
ted with 100 U/ml of penicillin-streptomycin (Nacalai Tes-
que). A CHO-K1 cell line stably expressing the fusion
GFP-TrkB was established by transfecting CHO-K1 cells
with the pGFP-TrkB plasmid, followed by selection with
1.0 mg/ml of G418 (Nacalai Tesque). The established cells
were treated with (+) or without (-) 10 μg/ml BFA for
12 h at 37°C.
Chemical crosslinking
CHO cells expressing the fusion construct GFP-TrkB were
cultured to a concentration of ~10
7 cells/dish (10 cm in
diameter; Iwaki Asahi Techno Glass, Chiba, Japan) before
chemical crosslinking. The cells were serum-starved for
2 h at 37°C, incubated on ice for another 1.0 h, and then
incubated in IMDM containing 0.45 M sucrose for 20 min
at 37°C. In the presence of 0.45 M sucrose, the cells were
treated with or without 100 ng/ml of BDNF (Alomone
Labs, Jerusalem, Israel) at a final concentration for 5 min
at 37°C. Then, the cells were treated with or without
1.0 mM BS
3 (Pierce Biotechnology, Rochford, IL) at a final
concentration in Dulbecco’s phosphate-buffered saline
(DPBS; Invitrogen), which contained 0.45 M sucrose, for
20 min at 37°C. This crosslinking reaction was quenched
by adding 40 mM Tris-HCl, pH 8.0, and 0.45 M sucrose at
final concentrations, followed by incubation for 15 min at
room temperature. After being washed twice with ice-cold
DPBS, the cells were lysed with NP-40 lysis buffer (50 mM
Tris-HCl, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM
NaF, 1.0 mM Na3VO4, 1.0% Nonidet P-40) supplemented
with a protease inhibitor cocktail (Nakalai Tesque) and a
phosphatase inhibitor cocktail (Nacalai Tesque) for 30
min at 4°C. Resulting cell lysates were sonicated twice for
5 s each, and centrifuged at 10,000 rpm for 10 min at 4°C.
The supernatants were collected for Western blotting.
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Cell lysates, 10 μg each as the amount of total protein per
lane, were loaded to NuPAGE 4-12% Bis-Tris gels (Invi-
trogen), followed by electrophoresis using XCell SureLock
Mini-Cell (Invitrogen) and transferred onto Hybond-P
PVDF membrane (Amersham Bioscences, Little Chalfont,
UK) using a mini Trans-Blot electrophoretic transfer cell
(Bio-Rad). The membrane was blocked overnight at 4°C in
TBST (10 mM Tris-HCl, pH7.6, 0.9% NaCl, 0.1% Tween
20) supplemented with 5% skimmed milk (Wako Pure
Chemical, Osaka, Japan) or in TBST supplemented with
2% ECL advance blocking agent (GE Healthcare, Little
Chalfont, UK), and was then incubated with the following
primary antibody in blocking buffer for 2 h at room tem-
perature: anti-TrkB monoclonal antibody (mAb) (1:500
dilution; Novus Biologicals, Littleton, CO), anti-phospho-
TrkA (Tyr674/675)/TrkB (Tyr706/707) (C50F3) rabbit
mAb (1:000 dilution; Cell Signaling Technology, Tokyo,
Japan), or mouse mAb against a-tubulin (1:2000 dilution;
Sigma-Aldrich Japan, Tokyo). The membrane was washed
three times with TBST, and was then incubated with
sheep anti-mouse or donkey anti-rabbit secondary anti-
body conjugated with horseradish peroxidase (1:10000
dilution; GE Healthcare) in the same blocking mixture for
90 min at room temperature. After being washed four
times with TBST, the membrane was reacted with an ECL
advance Western blotting detection kit (GE Healthcare).
Protein bands were visualized using a lumino-image analy-
ser (LAS3000; Fujifilm, Tokyo, Japan).
Immunofluorescent staining
Immunofluorescent staining was performed as previously
described [12]. HEK 293 cells (~2 × 10
4 cells/well) were
seeded into an eight-well Lab-Tek II chamber slide (Nalge
Nunc International, Naperville, IL), and then transfected
with or without expression plasmids of interest. After
washing twice with ice-cold 1 × PBS, the cells were fixed
with methanol-acetone (1:1) for 10 min at -20°C. After
being blocked with a mixture of Blocking One-P (Nakalai
Tesque) and 2% ECL Advance Blocking Agent (GE
Healthcare) and 50 mM NaF for 1.0 h at room tempera-
ture, the cells were incubated with the following primary
antibodies diluted in blocking buffer for 1.0 h at room
temperature: rabbit mAb against phospho-TrkA (Tyr490)/
TrkB (Tyr516) (Cell Signaling Technology) and rabbit
anti-calnexin antibody (Sigma). After washed three times
with TBST, the cells were incubated with the following
secondary antibodies diluted in blocking buffer for 1.0 h at
room temperature: Alexa Fluor 633-conjugated goat anti-
rabbit IgG (H+L) antibody (Molecular Probes, Eugene,
OR). After washed three times with TBST, the cells were
mounted in Vectashield (Vector Laboratories, Burlingame,
CA) and observed under an Axiovert 200 M inverted
microscope equipped with an LSM 510 META Ver 3.5
scan head (Carl Zeiss, Jena, Germany), using 488 nm
(argon) and 633 nm (HeNe) (Titanium:Sapphire from Mai
Tai; Spectra-Physics, Mountain View, CA) laser lines for
excitation of Venus and Alexa Fluor 633, respectively.
Firefly LFC
HEK 293 cells were plated in a 96-well black polystyrene
borosilicate glass microplate (Iwaki) at a concentration
of ~8,000 cells/well 12 h before transfection. Then the
cells were transfected with 50 ng of the control vector
pGL3 (Promega, Madison, WI), which encoded a full-
length luciferase, or with 100 ng each of expression
plasmid constructs by using 0.1 μl of Plus Reagent (Invi-
trogen) and 0.25 μl of Lipofectamin LTX Reagent (Invi-
trogen) in 20 μl of Opti-MEM I reduced serum medium
(Invitrogen). Forty hours after transfection, the cells
were serum-starved for 3 h, washed once with DPBS,
and then incubated in 100 μl of DPBS, which contained
0.15 mg/ml D-luciferin (Promega) as well as 0 ng/ml, 50
n g / m lo r1 0 0n g / m lB D N Fa taf i n a lc o n c e n t r a t i o n ,f o r
10 min at room temperature. After being incubated in
50 μl DPBS containing 0.45 M sucrose for 10 min at
room temperature, alternatively, the transfected cells
were incubated with 50 μl DPBS, which contained 0.45
M sucrose and 0.15 mg/ml D-luciferin at final concen-
trations, in the presence or absence of 100 ng/ml BDNF
at a final concentration at 37°C. Then, bioluminescence
intensity was measured by using a LAS 3000 or a micro-
plate luminometer, LB 960 Centro (Berthold Japan,
Osaka). Data are presented as the mean ± S.D. of tripli-
cate measurements. Statistical significance was assessed
using Student’s t-test. The P values less than 0.01 were
assessed to be statistically significant.
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